KATHERINE M BISHOP

Summary

Publications

  1. ncbi Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons
    Kathie M Bishop
    Ceregene, Inc, 9381 Judicial Drive, Suite 130, San Diego, CA 92121, USA
    Exp Neurol 211:574-84. 2008
  2. ncbi AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease
    Mehdi Gasmi
    Ceregene Inc, San Diego, CA 92121, USA
    Neurobiol Dis 27:67-76. 2007
  3. ncbi Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease
    Christopher D Herzog
    Ceregene, Inc, San Diego, California, USA
    Neurosurgery 64:602-12; discussion 612-3. 2009

Collaborators

Detail Information

Publications3

  1. ncbi Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons
    Kathie M Bishop
    Ceregene, Inc, 9381 Judicial Drive, Suite 130, San Diego, CA 92121, USA
    Exp Neurol 211:574-84. 2008
    ....
  2. ncbi AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease
    Mehdi Gasmi
    Ceregene Inc, San Diego, CA 92121, USA
    Neurobiol Dis 27:67-76. 2007
    ..These results support the ongoing CERE-120 clinical program in PD patients...
  3. ncbi Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease
    Christopher D Herzog
    Ceregene, Inc, San Diego, California, USA
    Neurosurgery 64:602-12; discussion 612-3. 2009
    ....